These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36527880)
1. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. Ma J; Zhou Q; Xu W; Li C; Wang H; Zhai Z; Zhang Y; Wahafu W Int Immunopharmacol; 2023 Jan; 114():109535. PubMed ID: 36527880 [TBL] [Abstract][Full Text] [Related]
2. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436 [TBL] [Abstract][Full Text] [Related]
3. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636 [TBL] [Abstract][Full Text] [Related]
4. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features. Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519 [TBL] [Abstract][Full Text] [Related]
5. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
6. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples. Gulinac M; Dikov D; Velikova T; Belovezhdov V Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081 [TBL] [Abstract][Full Text] [Related]
7. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951 [TBL] [Abstract][Full Text] [Related]
8. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100 [TBL] [Abstract][Full Text] [Related]
9. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency. Sungu N; Kıran MM Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535 [TBL] [Abstract][Full Text] [Related]
10. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target. Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis. Zhang J; Song L; Zhu H; Liu Q; Wang D Front Immunol; 2022; 13():986911. PubMed ID: 36248912 [TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263. Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047 [TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma - Madureira AC Front Immunol; 2022; 13():955000. PubMed ID: 36148227 [No Abstract] [Full Text] [Related]
15. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351 [TBL] [Abstract][Full Text] [Related]
16. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201 [TBL] [Abstract][Full Text] [Related]